The "Global Needle free Injector Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023" report has been added to ResearchAndMarkets.com's offering.

The key factors driving the market growth are increasing incidence of chronic diseases, rising incidence of communicable diseases due to needlestick injuries, growing demand for self-injection devices and advantages of drug delivery technology. However, the key restraining factors such as availability of alternative modes of drug delivery such as thin film drug delivery, magnetic drug delivery, self-micro emulsifying drug delivery system, acoustic targeted drug delivery etc. is expected to hinder the growth of global needle free injector market.

North America is the dominant region for global needle free injector market. This is due to the rising prevalence of chronic diseases, such as Alzheimer's, cancer, stroke, etc. Heart stroke is the third leading cause of death in United States. Furthermore, in 2016, approximately 1,685,210 new cases of cancer were diagnosed in United States and around 595,690 people died from cancer. However, Europe is the fastest growing market during forecast period 2016-2023 due to the rising demand for biologics in the European region.

The global needle free injector market is influenced by the presence of key market players such as Endo international PLC, Crossject, AstraZeneca, Asia Pharma Pharmaceutical ltd., etc. Product launch, joint venture, merger and acquisition are some of the crucial strategies adopted by the key market players to gain competitive advantage.

Market Determinants

Market Drivers

  • Increasing Incidence of Chronic Diseases
  • Rising Incidence of Communicable Diseases Due to Needle Stick Injuries
  • Growing Demand for Self-Injection Devices
  • Advantages of Drug Delivery Technology

Market Restraints

  • Alternative Modes of Drug Delivery

Market Opportunities

  • Growing Demand for Biosimilars and Vaccination
  • Emerging Markets of Needle Free Injection

Market Challenges

  • Need to Ensure System Sterility
  • Higher Cost of Development

Key Topics Covered:

1. Introduction

2. Market Overview

3. Market Determinants

4. Market Segmentation

5. Competitive Landscape

6. Geographic Analysis

7. Company Profiles

  • Asia Pharma Pharmaceutical Ltd (Malaysia)
  • Astrazeneca(England)
  • Bioject Medical Technologies (U.S.)
  • Crossject (France)
  • Endo International Plc (U.S.)
  • Envision Pharma Group (England)
  • Injex Pharma Ag (Germany)
  • Inovio Pharmaceuticals Inc. (U.S.)
  • Medical International Technology Inc. (Canada)
  • Merck (U.S.)
  • Mylan (U.S.)
  • National Medical Products Inc. (U.S.)
  • Pharmajet (U.S.)
  • Valeritas Inc. (U.S.)
  • Zogenix (U.S.)

For more information about this report visit https://www.researchandmarkets.com/research/hhr23r/global?w=4